US7022683B1
(en)
*
|
1998-05-13 |
2006-04-04 |
Carrington Laboratories, Inc. |
Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
|
US20030206958A1
(en)
*
|
2000-12-22 |
2003-11-06 |
Cattaneo Maurizio V. |
Chitosan biopolymer for the topical delivery of active agents
|
US6777000B2
(en)
*
|
2001-02-28 |
2004-08-17 |
Carrington Laboratories, Inc. |
In-situ gel formation of pectin
|
US7494669B2
(en)
*
|
2001-02-28 |
2009-02-24 |
Carrington Laboratories, Inc. |
Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
CN1253220C
(zh)
*
|
2001-06-29 |
2006-04-26 |
贝克顿迪肯森公司 |
通过微管在真皮内输入疫苗和基因治疗剂
|
WO2003072016A2
(en)
*
|
2001-11-19 |
2003-09-04 |
Becton, Dickinson And Company |
Pharmaceutical compositions in particulate form
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
AU2003274511B2
(en)
|
2002-10-11 |
2009-06-04 |
Glaxosmithkline Biologicals S.A. |
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
|
DK2279746T3
(da)
|
2002-11-15 |
2013-11-25 |
Novartis Vaccines & Diagnostic |
Overfladeproteiner i neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US20050106178A1
(en)
*
|
2003-01-30 |
2005-05-19 |
Chiron Corporation |
Adjuvanted influenza vaccine
|
WO2004067030A2
(en)
|
2003-01-30 |
2004-08-12 |
Chiron Srl |
Injectable vaccines against multiple meningococcal serogroups
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
EP1618127B1
(de)
|
2003-04-10 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenische Zusammensetzung einer Spikeprotein des SARS Coronavirus
|
EP1622448A2
(de)
*
|
2003-05-01 |
2006-02-08 |
West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited |
Nasale verabreichung des lh-rh-analogs leuprolid
|
US7588774B2
(en)
*
|
2003-05-12 |
2009-09-15 |
Becton, Dickinson And Company |
Molecules enhancing dermal delivery of influenza vaccines
|
US20050123550A1
(en)
*
|
2003-05-12 |
2005-06-09 |
Laurent Philippe E. |
Molecules enhancing dermal delivery of influenza vaccines
|
GB0315632D0
(en)
|
2003-07-04 |
2003-08-13 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical formulations
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
ES2397923T3
(es)
|
2003-10-02 |
2013-03-12 |
Novartis Ag |
Vacunas líquidas para múltiples serogrupos meningocócicos
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
EP1708742A4
(de)
*
|
2003-12-05 |
2008-11-05 |
Becton Dickinson Co |
Verfahren zur verbesserung der immunantwort im intradermalen kompartiment und dafür nützliche verbindungen
|
US7968122B2
(en)
*
|
2003-12-10 |
2011-06-28 |
Adventrx Pharmaceuticals, Inc. |
Anti-viral pharmaceutical compositions
|
DE202005022108U1
(de)
|
2004-03-09 |
2013-11-12 |
Novartis Vaccines And Diagnostics, Inc. |
Influenza-Virus-Impfstoffe
|
DK1740217T3
(da)
|
2004-04-30 |
2011-09-26 |
Novartis Ag |
Meningokok-konjugat-vaccination
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
JP2007536259A
(ja)
*
|
2004-05-06 |
2007-12-13 |
イヴレア ファーマスーティカルズ インコーポレイテッド |
活性薬剤の送達のための粒子
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP1766034B1
(de)
|
2004-05-21 |
2014-03-19 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus-vektoren für impfstoffe gegen das influenza virus
|
EP2612679A1
(de)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogene Zusammensetzungen für grampositive Bakterien wie etwa Streptococcus agalactiae
|
EP2179744B1
(de)
|
2004-09-09 |
2010-12-01 |
Novartis Vaccines and Diagnostics GmbH |
Verminderung von potentiellen iatrogenen Risiken in Verbindung mit Influenza Impfstoffen
|
CA2577336A1
(en)
*
|
2004-09-15 |
2006-03-23 |
Otsuka Pharmaceutical Co., Ltd. |
Permucosal composition and method of improving permucosal absorption
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
US20090004222A1
(en)
|
2004-11-03 |
2009-01-01 |
O'hagan Derek |
Influenza Vaccination
|
US20060121055A1
(en)
*
|
2004-12-06 |
2006-06-08 |
Becton, Dickinson And Company, Inc. |
Compositions with enhanced immunogenicity
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
*
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
MX291624B
(es)
|
2005-02-18 |
2011-11-04 |
Novartis Vaccines & Diagnostic |
Inmunogenos de escherichia coli uropatogenica.
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
US20070059319A1
(en)
*
|
2005-09-15 |
2007-03-15 |
Caliper Life Sciences, Inc. |
Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
PT2368572T
(pt)
|
2005-11-04 |
2020-06-16 |
Seqirus Uk Ltd |
Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
|
CA2630220C
(en)
*
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
KR20080089663A
(ko)
|
2006-01-27 |
2008-10-07 |
노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 |
적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
|
EP1991204A2
(de)
|
2006-02-24 |
2008-11-19 |
Novartis AG |
Mikropartikel mit biologisch abbaubarem polymer und kationischem polysaccharid zur verwendung für immunogene zusammensetzungen
|
ATE539079T1
(de)
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
AU2007231027B2
(en)
|
2006-03-24 |
2013-10-03 |
Novartis Influenza Vaccines Marburg Gmbh |
Storage of influenza vaccines without refrigeration
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
PT2054431E
(pt)
|
2006-06-09 |
2011-11-03 |
Novartis Ag |
Confórmeros de adesinas bacterianas
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
AU2007297178B2
(en)
|
2006-09-11 |
2014-07-24 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
US8080645B2
(en)
*
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
US9598462B2
(en)
|
2012-01-26 |
2017-03-21 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
WO2008068631A2
(en)
|
2006-12-06 |
2008-06-12 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
JP5502494B2
(ja)
|
2007-01-22 |
2014-05-28 |
ターガセプト・インコーポレイテッド |
メタニコチンアナログの鼻腔内、バッカル、または舌下投与
|
US20080182819A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Act Iii Licensing, Llc |
Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
|
NZ582595A
(en)
|
2007-06-27 |
2012-07-27 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
JP5259997B2
(ja)
*
|
2007-07-24 |
2013-08-07 |
大日精化工業株式会社 |
免疫アジュバント分散液
|
JP5297009B2
(ja)
*
|
2007-07-24 |
2013-09-25 |
大日精化工業株式会社 |
免疫アジュバント水溶液
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
US8821885B2
(en)
|
2007-08-27 |
2014-09-02 |
Longhorn Vaccines & Diagnostics, Llc |
Immunogenic compositions and methods
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
MX2010002773A
(es)
|
2007-09-12 |
2010-03-31 |
Novartis Ag |
Antigenos mutantes de gas57 y anticuerpos de gas57.
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
WO2009085355A2
(en)
|
2007-10-01 |
2009-07-09 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection and transport system and methods of use
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
JP5656642B2
(ja)
|
2007-12-21 |
2015-01-21 |
ノバルティス アーゲー |
ストレプトリシンoの変異体形態
|
CA2716212A1
(en)
|
2008-02-21 |
2009-08-27 |
Novartis Ag |
Meningococcal fhbp polypeptides
|
JP2009209086A
(ja)
*
|
2008-03-04 |
2009-09-17 |
Masami Moriyama |
粘膜投与型ワクチン
|
NZ587798A
(en)
|
2008-03-18 |
2013-06-28 |
Novartis Ag |
Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
|
CN102481349B
(zh)
|
2009-01-12 |
2014-10-15 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
EP2403526B1
(de)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Chlamydia-antigene
|
JP5830009B2
(ja)
|
2009-04-14 |
2015-12-09 |
ノバルティス アーゲー |
Staphylococcusaureusに対して免疫化するための組成物
|
DK2442826T3
(en)
|
2009-06-15 |
2015-09-21 |
Univ Singapore |
Influenza vaccine, composition and methods of using
|
WO2010151076A2
(ko)
*
|
2009-06-25 |
2010-12-29 |
주식회사 바이오리더스 |
폴리감마글루탐산-키토산 나노입자를 함유하는 면역보강제 조성물
|
US9907746B2
(en)
|
2009-07-06 |
2018-03-06 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
CA2767392C
(en)
|
2009-07-06 |
2017-03-14 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
US20120164176A1
(en)
|
2009-07-15 |
2012-06-28 |
Kurt Swanson |
Rsv f protein compositions amd methods for making same
|
SG178035A1
(en)
|
2009-07-16 |
2012-03-29 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
JP2013502918A
(ja)
|
2009-08-27 |
2013-01-31 |
ノバルティス アーゲー |
髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
|
JP2011057605A
(ja)
*
|
2009-09-09 |
2011-03-24 |
Masami Moriyama |
粘膜投与型ワクチン
|
US20120237536A1
(en)
|
2009-09-10 |
2012-09-20 |
Novartis |
Combination vaccines against respiratory tract diseases
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
US8974799B2
(en)
|
2009-09-30 |
2015-03-10 |
Novartis Ag |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
US20130022639A1
(en)
|
2009-09-30 |
2013-01-24 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
EP2493499A1
(de)
|
2009-10-27 |
2012-09-05 |
Novartis AG |
Modifizierte meningokokken-fhbp-polypeptide
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
US8765148B2
(en)
*
|
2010-02-19 |
2014-07-01 |
Valneva Austria Gmbh |
1C31 nanoparticles
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
JP2013529894A
(ja)
|
2010-04-07 |
2013-07-25 |
ノバルティス アーゲー |
パルボウイルスb19のウイルス様粒子を生成するための方法
|
EP2558069A1
(de)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridinzusammensetzungen und ihre verwendung
|
RU2465006C2
(ru)
*
|
2010-04-14 |
2012-10-27 |
Учреждение Российской академии медицинских наук научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова РАМН (НИИВС им. И.И. Мечникова РАМН) |
Способ повышения иммуногенности холодоадаптированной живой гриппозной вакцины
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
CA2840079C
(en)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
CA2804501C
(en)
|
2010-07-06 |
2021-01-26 |
Novartis Ag |
Noro virus derived immunogenic compositions and methods
|
CA2812135A1
(en)
|
2010-09-07 |
2012-03-15 |
Novartis Ag |
Generic assays for detection of mammalian reovirus
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
WO2012085668A2
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
MX359103B
(es)
|
2011-01-13 |
2018-09-14 |
Variation Biotechnologies Inc |
Composiciones y sus usos en el tratamiento de infecciones virales.
|
US20130323280A1
(en)
|
2011-01-13 |
2013-12-05 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
ES2727836T3
(es)
|
2011-01-26 |
2019-10-21 |
Glaxosmithkline Biologicals Sa |
Régimen de inmunización del VRS
|
CA2835644C
(en)
|
2011-05-13 |
2021-06-15 |
Novartis Ag |
Pre-fusion rsv f antigens
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
EP2729178A1
(de)
|
2011-07-08 |
2014-05-14 |
Novartis AG |
Tyrosinverbindungsverfahren
|
EP2736921B1
(de)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Zusammensetzungen und verfahren zum testen der funktionellen immunogenität von parvovirus-impfstoffen
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
JP2014531442A
(ja)
|
2011-09-14 |
2014-11-27 |
ノバルティス アーゲー |
Escherichiacoliワクチンの組み合わせ
|
TR201909110T4
(tr)
|
2011-09-14 |
2019-07-22 |
Glaxosmithkline Biologicals Sa |
Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
|
MX354924B
(es)
|
2011-11-07 |
2018-03-22 |
Novartis Ag |
Molecula portadora que comprende un antigeno spr0096 y un spr2021.
|
US20140328876A1
(en)
|
2011-11-18 |
2014-11-06 |
Variation Biotechnologies Inc. |
Synthetic derivatives of mpl and uses thereof
|
WO2013084071A2
(en)
|
2011-12-08 |
2013-06-13 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
WO2013104995A2
(en)
|
2012-01-12 |
2013-07-18 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating viral infections
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
WO2013111012A2
(en)
|
2012-01-27 |
2013-08-01 |
Variation Biotechnologies, Inc. |
Methods and compositions for therapeutic agents
|
WO2013124473A1
(en)
|
2012-02-24 |
2013-08-29 |
Novartis Ag |
Pilus proteins and compositions
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
EP3804749A3
(de)
|
2012-04-26 |
2021-07-28 |
GlaxoSmithKline Biologicals S.A. |
Antigenen und kombinationene von antigenen
|
US10124051B2
(en)
|
2012-05-22 |
2018-11-13 |
Glaxosmithkline Biologicals Sa |
Meningococcus serogroup X conjugate
|
CN104853770A
(zh)
|
2012-07-06 |
2015-08-19 |
诺华股份有限公司 |
免疫原性组合物及其应用
|
WO2014043518A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
RU2662970C2
(ru)
|
2012-09-18 |
2018-07-31 |
Новартис Аг |
Везикулы наружной мембраны
|
CA2885625A1
(en)
|
2012-10-02 |
2014-04-10 |
Glaxosmithkline Biologicals S.A. |
Nonlinear saccharide conjugates
|
AR092897A1
(es)
|
2012-10-03 |
2015-05-06 |
Novartis Ag |
Composiciones inmunogenicas
|
WO2014070709A1
(en)
|
2012-10-29 |
2014-05-08 |
The Board Of Trustees Of The University Of Arkansas |
Novel mucosal adjuvants and delivery systems
|
SI2925355T1
(en)
|
2012-11-30 |
2018-04-30 |
Glaxosmithkline Biologicals S.A. |
Antigens and combinations of Pseudomonas antigens
|
EP2870974A1
(de)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella-Konjugatimpfstoffe
|
WO2016183292A1
(en)
|
2015-05-14 |
2016-11-17 |
Longhorn Vaccines And Diagnostics, Llc |
Rapid methods for the extraction of nucleic acids from biological samples
|
EP4114848A4
(de)
|
2020-02-26 |
2024-04-03 |
Versitech Limited |
Auf pd-1 basierende vakzine gegen coronavirusinfektion
|
WO2022234483A1
(en)
|
2021-05-04 |
2022-11-10 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2024130009A1
(en)
|
2022-12-14 |
2024-06-20 |
Yale University |
Compositions and methods of use thereof for the treatment of virally driven cancers
|